Citigroup Inc. reissued their buy rating on shares of Shire PLC (LON:SHP) in a report issued on Monday morning, MarketBeat reports. They currently have a GBX 5,500 ($72.58) target price on the biopharmaceutical company’s stock.
Several other equities analysts have also issued reports on the company. J P Morgan Chase & Co restated an overweight rating and set a GBX 5,300 ($69.94) price target on shares of Shire PLC in a research report on Monday. Deutsche Bank AG restated a buy rating and set a GBX 5,700 ($75.22) price target on shares of Shire PLC in a research report on Thursday, October 26th. Shore Capital restated a buy rating on shares of Shire PLC in a research report on Thursday, October 26th. Berenberg Bank reduced their price target on Shire PLC from GBX 6,000 ($79.18) to GBX 5,900 ($77.86) and set a buy rating on the stock in a research report on Tuesday, October 24th. Finally, Liberum Capital reduced their price target on Shire PLC from GBX 4,400 ($58.06) to GBX 4,200 ($55.42) and set a hold rating on the stock in a research report on Tuesday, October 24th. Four investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of Buy and a consensus price target of GBX 5,509.68 ($72.71).
TRADEMARK VIOLATION NOTICE: This piece of content was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.com-unik.info/2017/11/02/shire-plcs-shp-buy-rating-reiterated-at-citigroup-inc.html.
In other news, insider Flemming Ornskov bought 8,400 shares of the stock in a transaction dated Tuesday, August 22nd. The stock was bought at an average price of GBX 3,665 ($48.36) per share, for a total transaction of £307,860 ($406,254.95). Also, insider Anne Minto bought 190 shares of the stock in a transaction dated Friday, September 29th. The stock was purchased at an average price of GBX 3,785 ($49.95) per share, with a total value of £7,191.50 ($9,489.97).
Shire PLC Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
What are top analysts saying about Shire PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Shire PLC and related companies.